Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of
which more than 65% cases are diagnosed in advanced stages, requiring platinum-based …

Objectives This study aimed to evaluate serum human epididymis protein 4 (HE4) changes
during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff …

Background This study assessed the prognostic value of HE4 marker measurements at
various stages of first-line chemotherapy for ovarian cancer. Methods The study consisted of …

Objectives To assess the prognostic value of human epididymis protein 4 (HE4) kinetics
during and after neoadjuvant chemotherapy (NACT) cycles compared with cancer antigen …

Abstract Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian
cancer (EOC). Data on its profile and predictive potential for subsequent outcome after …

OBJECTIVES: Epithelial ovarian cancer (EOC) is the major cause of death due to
gynecological malignancies. The most important prognostic factors are residual tumor mass …

Objective Human epididymis protein 4 (HE4) is a promising novel serum biomarker for the
detection of early-stage epithelial ovarian cancer (EOC) and for the differential diagnosis …

Objective: Human epididymis protein 4 (HE4) has attracted a lot of interest as a relatively
novel biomarker for ovarian carcinoma. Research focus has been directed at HE4 as a …

Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers.
Optimal tumor debulking, no matter the primary or the interval, is the most important …

Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human
epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim …